Canada Markets closed

Tiziana Life Sciences PLC (TLSA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.8500+0.0473 (+5.89%)
At close: 04:00PM EST
0.8500 0.00 (0.00%)
After hours: 05:17PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.8027
Bid0.8000 x 1200
Ask0.8500 x 1200
Day's Range0.7736 - 0.8600
52 Week Range0.6600 - 4.9900
Avg. Volume141,282
Market Cap82.71M
Beta (5Y Monthly)-0.02
PE Ratio (TTM)N/A
EPS (TTM)-0.2200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
  • GlobeNewswire

    Tiziana Life Sciences Ltd. To Implement Stock Repurchase Program for up to $5 Million

    NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that its Board of Directors has today authorized the Company’s management to implement a stock repurchase program for up to $5 million of the Company’s common shares at any time. The term of the board authorization is until December 31, 2022. The repurchase program may be suspended or discontinued at any time and will be funded using the Company’s working capital. Executive Chairman Gabriele Cerrone c

  • GlobeNewswire

    Tiziana Life Sciences Announces Death of Director

    NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that Dr. Thomas Adams passed away on January 9, 2022. He served as a member of Tiziana Life Science’s Board of Directors since February 2021. Dr. Kunwar Shailubhai, the Company's CEO, commented, "It is with great sadness that we announce the passing of Dr. Tom Adams. He was a highly valued Di

  • GlobeNewswire

    Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis

    - Clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatment was well tolerated with a favorable clinical response - FDA allows for continued enrollment under the Individual Patient Expanded Access Program NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, is pleased to announce that the U.S. Food an